

This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository: <https://orca.cardiff.ac.uk/id/eprint/173774/>

This is the author's version of a work that was submitted to / accepted for publication.

Citation for final published version:

Mukherjee, Somnath, Qi, Cathy, Shaw, Rachel, Jones, Christopher M., Bridgewater, John A., Radhakrishna, Ganesh, Patel, Neel, Holmes, Jane, Virdee, Pradeep S., Tranter, Bethan, Parsons, Philip, Falk, Stephen, Wasan, Harpreet S., Ajithkumar, Thankamma V., Holyoake, Daniel, Roy, Rajarshi, Scott-Brown, Martin, Hurt, Christopher N., O'Neill, Eric, Sebag-Montefiore, David, Maughan, Tim S., Hawkins, Maria A. and Corrie, Pippa 2024. Standard or high dose chemoradiotherapy, with or without the protease inhibitor nelfinavir, in patients with locally advanced pancreatic cancer: The phase 1/randomised phase 2 SCALOP-2 trial. *European Journal of Cancer* 209 , 114236. 10.1016/j.ejca.2024.114236

Publishers page: <http://dx.doi.org/10.1016/j.ejca.2024.114236>

Please note:

Changes made as a result of publishing processes such as copy-editing, formatting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You are advised to consult the publisher's version if you wish to cite this paper.

This version is being made available in accordance with publisher policies. See <http://orca.cf.ac.uk/policies.html> for usage policies. Copyright and moral rights for publications made available in ORCA are retained by the copyright holders.



Standard or high dose chemoradiotherapy, with or without the protease inhibitor nelfinavir, in patients with locally advanced pancreatic cancer: the phase 1/randomised phase 2 SCALOP-2 trial

Somnath Mukherjee FRCR¹, Cathy Qi MSc², Rachel Shaw BA³, Christopher M. Jones PhD^{4,5}, John A. Bridgewater PhD⁶, Ganesh Radhakrishna FRCR⁷, Neel Patel DPhil⁸, Jane Holmes MSc², Pradeep S. Virdee DPhil², Bethan Tranter MSc⁹, Philip Parsons MSc⁹, Stephen Falk FRCR¹⁰, Harpreet S. Wasan FRCP¹¹, Thankamma V. Ajithkumar FRCR⁵, Daniel Holyoake FRCR¹², Rajarshi Roy FRCR¹³, Martin Scott-Brown FRCR¹⁴, Christopher N. Hurt PhD¹⁵, Eric O'Neill¹⁶, David Sebag-Montefiore FRCR¹⁷, Tim S Maughan FRCR¹⁸, Maria A Hawkins FRCR¹⁹ & Pippa Corrie FRCP⁵

¹ Oxford Cancer Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK

² Centre for Statistics in Medicine, University of Oxford, Oxford, UK

³Oncology Clinical Trials Office (OCTO), Department of Oncology, University of Oxford, Oxford, UK

⁴Department of Oncology, University of Cambridge, Cambridge, UK

⁵ Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK

⁶ UCL Cancer Institute, University College London Hospitals NHS Foundation Trust, London, UK

⁷ The Christie Hospital, The Christie Hospitals NHS Foundation Trust, Manchester, UK

⁸ Department of Radiology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK

⁹ Velindre Cancer Centre, Velindre University NHS Trust, Cardiff, UK

¹⁰ Bristol Cancer Centre, University Hospitals Bristol NHS Foundation Trust, Bristol, UK

¹¹ Department of Surgery & Cancer, Imperial College London, London, UK

¹² Norfolk & Norwich University Hospital, Norfolk & Norwich University Hospitals NHS Foundation Trust, Norwich, UK

¹³ Queen's Centre for Oncology, Hull University Teaching Hospitals NHS Trust, Hull, UK

¹⁴ Coventry Cancer Centre, University Hospital Coventry & Warwickshire, Coventry, UK

¹⁵ Centre for Trials Research, Cardiff University, Cardiff, UK

¹⁶ Department of Oncology, University of Oxford, Oxford, UK

¹⁷ Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, UK

¹⁸ Oxford Institute for Radiation Oncology, University of Oxford, Oxford, UK

¹⁹ Department of Medical Physics & Biomedical Engineering, University College London, London, UK

*Correspondence to: Prof. Somnath Mukherjee
Oxford Cancer Centre
Oxford University Hospitals NHS Foundation Trust
Level 2 Admin, Churchill Hospital
Oxford, OX3 7LE, United Kingdom

Email: somnath.mukherjee@ouh.nhs.uk

Tel: +44 (0) 1865 235 207

Word count: 3027 words

ABSTRACT

Background: The multi-centre two-stage SCALOP-2 trial (ISRCTN50083238) assessed whether dose escalation of consolidative chemoradiotherapy (CRT) or concurrent sensitization using the protease inhibitor nelfinavir improve outcomes in locally advanced pancreatic cancer (LAPC) following four cycles of gemcitabine/nab-paclitaxel.

Methods: In stage 1, the maximum tolerated dose (MTD) of nelfinavir concurrent with standard-dose CRT (50.4Gy in 28 fractions) was identified from a cohort of 27 patients. In stage 2, 159 patients were enrolled in an open-label randomized controlled comparison of standard versus high dose (60Gy in 30 fractions) CRT, with or without nelfinavir at MTD. Primary outcomes following dose escalation and nelfinavir use were respectively overall survival (OS) and progression free survival (PFS). Secondary endpoints included health-related quality of life (HRQoL).

Results: High dose CRT did not improve OS (16.9 (60% confidence interval, CI 16.2-17.7) vs. 15.6 (60%CI 14.3-18.2) months; adjusted hazard ratio, HR 1.13 (60%CI 0.91-1.40; p=0.68)). Similarly, median PFS was not improved by nelfinavir (10.0 (60%CI 9.9-10.2) vs. 11.1 (60%CI 10.3-12.8) months; adjusted HR 1.71 (60%CI 1.38-2.12; p=0.98)). Local progression at 12 months was numerically lower with high-dose CRT than with standard dose CRT (n=11/46 (23.9%) vs. n=15/45 (33.3%)). Neither nelfinavir nor radiotherapy dose escalation impacted on treatment compliance or grade 3/4 adverse event rate. There were no sustained differences in HRQoL scores between treatment groups over 28 weeks post-treatment.

Conclusions: Dose-escalated CRT may improve local tumour control and is well tolerated when used as consolidative treatment in LAPC but does not impact OS. Nelfinavir use does not improve PFS.

KEY WORDS

Pancreatic cancer; Chemoradiotherapy; Nelfinavir; Dose escalation; Survival; Outcomes; Toxicity; Health-related quality of life

INTRODUCTION

Pancreatic cancer is the seventh leading cause of cancer-related death worldwide, with a mortality to incidence ratio that exceeds 90%¹. Around a third of patients present with inoperable locally advanced pancreatic cancer (LAPC), which is broadly defined by an absence of metastases but extensive tumour contact with local vasculature that jeopardizes curative resection². There is uncertainty regarding the optimal management of patients with LAPC, although primary systemic therapy is established as the standard of care, due at least in part to a high propensity for early metastatic spread³⁻⁵.

Establishing local tumour control is important for increasing the proportion of patients eligible for a potentially curative resection as well as for reducing rates of local progression, which is a key cause of morbidity and which reportedly causes around 30% of deaths in this cohort^{6,7}. Correspondingly, European and American guidance suggest that CRT can be considered as consolidation therapy in symptomatic patients and in those who do not have progressive disease following upfront systemic therapy^{8,9}. Pancreatic cancers are, however, radioresistant and outcomes following CRT remain disappointing, with local failure rates persisting at 30-40% and a complete radiological or pathological response realized in less than 5% of patients¹⁰⁻¹².

A greater biological effect from radiotherapy may be achieved by dose escalation, or by optimizing strategies for tumour radiosensitisation. There has, however, been uncertainty regarding the feasibility of delivering higher radiation doses in the context of CRT given a relationship between treatment toxicity and dose to surrounding organs at risk (OARs) such as the stomach and duodenum^{13,14}. There are also no currently approved sensitization strategies beyond the use of cytotoxic chemotherapy. However, preclinical data suggest that the antiretroviral protease inhibitor nelfinavir promotes radiosensitisation of pancreatic cancer cells via the downregulation of phosphorylation of Akt serine 473, which reduces activity of the PI3K/Akt pathway, even in cells that have a mutation of *KRAS*¹⁵⁻¹⁸. This is commonly overactive in pancreatic cancers but not in normal tissues, thereby theoretically allowing for the specific radiosensitisation of tumour cells. Adding to this, at the time of trial initiation two early phase studies evaluating nelfinavir use with pancreatic radiotherapy had shown promising outcomes, including a 50% complete radiological response rate and 1-year survival of 73%, without compromising toxicity^{19,20}.

Given this, in the Systemic therapy and Chemoradiation in Advanced Localised Pancreatic cancer (SCALOP)-2 trial reported here we sought to evaluate the safety, toxicity and efficacy of radiotherapy dose escalation and nelfinavir, alone and in combination, in patients with LAPC managed with capecitabine-based CRT.

METHODS

Study design and patients

The SCALOP-2 trial comprised of two stages. These are fully outlined in the study protocol, which has been published previously and which is included here as **Appendix 1**²¹. The first single-arm safety run-in stage focused on finding the maximum tolerated dose (MTD) of nelfinavir when used concurrently with standard dose (50.4Gy in 28 fractions) capecitabine-based CRT. The second stage commenced once the primary objective of stage 1 had been met and was a multi-centre, open-label, randomised 2 × 2 factorial + 1, phase II study that sought to answer two questions. Firstly, whether high dose capecitabine-based CRT (60Gy in 30 fractions) improves overall survival (OS) when compared to standard dose CRT and, secondly, whether the addition of nelfinavir at its MTD to standard- or high-dose CRT improves progression free survival (PFS).

Briefly, we recruited patients of at least 18 years in age who were of World Health Organisation (WHO) performance status (PS) 0 or 1 and who had histologically or cytologically proven pancreatic carcinoma. To be registered for the trial, patients were required to have computed tomography (CT) or positron emission tomography (PET)-CT imaging of the thorax, abdomen and pelvis in the six weeks prior to commencing treatment. The primary pancreatic lesion was required to measure 6cm or less by imaging, with the disease classified by a site-specialist multidisciplinary team as locally advanced and inoperable but non-metastatic using National Comprehensive Cancer Network criteria.

All patients had to provide written informed consent prior to registration, after which they would proceed within 21 days to commence an induction gemcitabine/nab-paclitaxel (gem/nabP) doublet. Eligibility for CRT was confirmed in those with responding or stable disease based on cross-sectional imaging, for whom the tumour could be encompassed within a radical radiotherapy treatment volume and who remained at a WHO PS of 0 or 1. In stage 2, patients were randomised once confirmed eligible.

The study was approved by the South Central – Oxford A Research Ethics Committee and by the UK Medicines and Healthcare Products Regulatory Agency. Data are reported here in compliance with the CONSolidated Standards of Reporting Trials (CONSORT) statement²².

Information relating to study governance and trial oversight is provided in **Appendix 2**, as is information on randomisation and masking as well as the study procedures.

Statistical analysis

All analyses were undertaken in accordance with a pre-specified statistical analysis plan. Stage 1 used the rolling-six design to establish the recommended dose of nelfinavir to be administered with CRT in stage 2. Participants who fulfilled the criteria for evaluability, including all participants with dose limiting toxicities (DLTs), were assessed. DLTs were defined as per CTCAE v4.03 as any grade 4 or above toxicity, any non-haematological grade 3 nelfinavir or treatment-related adverse event (AE) deemed clinically significant by the investigator, an inability to tolerate at least 20 fractions of RT due to an AE or a serious AE requiring a pause in RT of at least 14 days.

In stage 2, the two primary endpoints were PFS by nelfinavir arms (A+C vs. B+D), and OS by CRT arms (C+D vs. A+B). The estimated sample size was 168 recruited based on an assumption from SCALOP trial data that 65% would not progress through induction therapy and that 96 patients would therefore be randomised to arms A to D¹¹. This was the final revised calculation following the decision to close arm E and would detect a hazard ratio (HR) of ≤ 0.65 with 80% power and one-sided $\alpha=0.2$, accounting for 10% loss to follow-up for the PFS outcome and negligible loss to follow-up for the OS outcome. This calculation was based on an assumed median PFS of 12 months in the no nelfinavir arm and median OS of 15 months in the 50.4Gy arm. Secondary endpoints were PFS and one-year OS by RT assignment, OS by nelfinavir assignment, safety (as per CTCAE, version v4.03), resection rate, compliance with CRT, one-year local control, CA19-9, disease response at 6 weeks post-CRT treatment, and HRQoL.

Analyses were undertaken using Stata Statistical Software V15.1 (Stage 1) and V16.1 (stage 2), (StataCorp. College Station, TX: StataCorp LLC), and R version 3.3.2 (Stage 1). Analyses for stage 2 were done according to the intention-to-treat principle such that all randomised patients were included in their allocated group. Per-protocol analyses were conducted for the primary outcomes and included participants who received all prescribed fractions of CRT and, for arms A and C, at least 70% of nelfinavir. Safety analyses included all participants who received at least one dose of any protocol-specified treatment. For comparisons between CRT arms, all randomised patients were included. For comparisons between nelfinavir arms, concurrently randomised patients up to the date (26th February 2020) of arm A and C closure were included. Additional information relating to statistical analyses is included in **Appendix 2**.

This trial is registered with International Standard Randomised Controlled Trial Number (ISRCTN) 50083238.

Role of the funding source

Cancer Research UK and Celgene Ltd had no role in study design, data collection, data analysis, data interpretation, the writing of the study report or the decision to submit for publication. SM, CQ and CMJ had full access to the study data. SM had final responsibility for the decision to submit for publication.

RESULTS

Overview

For stage 1, 27 participants were registered from nine participating sites (**Supp. Table 1**) between March 2016 and May 2017. Eighteen of these were considered evaluable for MTD (**Supp. Fig. 1**). Recruitment for stage 2 took place in 23 sites between August 2017 and March 2020. Arm E was initially planned as a systemic therapy calibration arm but was closed to favour recruitment to arms A-D, with relevant systemic therapy calibration data provided through publication of the LAPACT trial²³. Study centre was dropped as a minimisation factor as recruiting centres at this stage exceeded 20 (**Supp. Table 1**). Trial recruitment was temporarily halted in February 2020 following advice from the data safety and monitoring committee (DSMC) and trial steering committee (TSC) to close nelfinavir treatment arms (A and C) relating to lack of efficacy, as outlined in **Appendix 2**. The coronavirus disease 2019 (COVID-19) pandemic significantly interrupted UK trials activity in March 2020 and as the SCALOP-2 trial was due to close to recruitment in May 2020, did not reopen. Patients already recruited proceeded to randomisation to the remaining open arms, B and D.

In total, 159 patients were recruited to stage 2, 150 of whom commenced gemcitabine/nabP. As outlined in **Supp. Table 2**, 33 (20.8%) of these did not reach the randomisation time point. Of the remaining 126 who were assessed for eligibility, 106 (84.1%) patients were randomised; 91 of whom were allocated to arms A-D (**Figure 1**). The reasons for ineligibility for randomisation are provided in **Supp. Table 2**. Whilst recruitment of 96 patients to arms A-D had been planned to capture 62 PFS events and 62 deaths, 75 PFS events and 64 deaths were seen with 91 patients.

Baseline characteristics

The baseline characteristics of patients enrolled in stages 1 and 2 are shown in **Supp. Table 3** and **Table 1**, respectively. Sex, performance status and the primary pancreatic tumour site (head versus body/tail) do not appear well balanced between the stage 2 arms. Median baseline CA19-9 level

appears to show variation between treatment arms but interquartile ranges are large. Relevant missing data items for stage 2 are summarised in **Supp. Table 4**.

Compliance & safety

Data relating to treatment compliance and safety are included in **Appendix 2**.

Primary endpoints

OS was assessable in all 91 randomised patients (**Fig. 2A; Supp. Figs. 2A & 2B**). Thirty-one (68.9%) of the 45 patients in the standard dose CRT arm died, compared with 33 (71.7%) of the 46 patients in the high-dose CRT arm. This translated to respective median OS of 15.6 (60%CI 14.3-18.2) months and 16.9 (60%CI 16.2-17.7) months (log-rank $p=0.68$, adjusted HR 1.13 (60%CI 0.91-1.40; adjusted $p=0.68$), adjusted p -value 0.68), and 1 year survival of 75.3% (60%CI 69.3-80.2) and 73.0% (60%CI 67.0-78.2)). PFS was assessable in all 76 patients randomised before the closure of arms A and C (**Fig. 2B; Supp. Figs. 3A & 3B**). Three patients died without progression. Thirty two (84.2%) of the 38 patients who did not receive nelfinavir had a progression event compared with 35 (92.1%) of the 38 patients who did receive nelfinavir; translating to respective median PFS of 11.1 (10.3-12.8) months and 10.0 (9.9-10.2) months (log-rank $p=0.98$, adjusted HR 1.71; 60%CI 1.38-2.12; adjusted $p=0.98$). Per-protocol analyses for OS and PFS were consistent with these data (**Supp. Table 11**). Sensitivity analyses did not identify an interactional effect from the factorial design of the trial for either of the primary endpoints (**Supp. Table 12**).

Secondary disease control endpoints

A summary of secondary endpoints relating to disease control is provided in **Table 4**. No difference was seen in PFS by radiation dose or OS by nelfinavir usage. A greater proportion of patients had stable or responding disease at 6-weeks post CRT with high-dose radiation than with standard dose radiation ($n=29/46$; 63.1% vs. $n=22/45$; 48.9%). In a post-hoc analysis of patients with evaluable imaging, this translated to a significantly greater disease control rate for high-dose versus standard dose radiation ($29/35$, 82.9% vs. $22/36$, 61.1%; chi-square $p=0.04$). Similarly, the rate of local progression at 12 months was lower with high-dose CRT ($n=11$; 23.9%) than with standard dose CRT ($n=15$; 33.3%), whilst $3/12$ (25.0%) patients in the high dose arm compared with $7/11$ (63.6%) in the standard dose CRT arm died after local progression (**Supp. Table 13**). The proportion of patients with local

progression by 12 months was similar with (n=12/38; 31.6%) or without (11/53; 28.9%) nelfinavir. Despite this, a lower proportion of patients treated with nelfinavir were progression free at 12 months (47.4%; n=18/53 vs. 28.9%; n=11/38) due to a higher rate of metastatic spread with nelfinavir (39.5%; n=15/38 vs. 23.7%; n=9/53). Resection rates were similar between standard and high dose CRT, and with or without nelfinavir use. There was no difference between arms in disease response rates or CA19-9 level (**Table 4**).

Survival and disease control data from arm E and the observation cohort are respectively presented in **Supp. Table 14** and **Supp. Table 15**.

Quality of life measures

A summary of data availability for each of the three HRQoL measures at each of the five assessed timepoints is provided in **Supp. Table 16**. The proportion of patients for whom data was available is higher for assessments up to six weeks post-CRT than after this timepoint. At the end of CRT, mean Global Health Status (GHS) score was respectively 66.7 (interquartile range, IQR 50,83.3) versus 75.0 (IQR 58.3, 83.3) for standard and high dose CRT, and 66.7 (IQR 50,83.3) versus 66.7 (58.3, 83.3) with and without nelfinavir. The EQ5D score at this timepoint was respectively 0.75 (IQR .66,.91) versus 0.84 for standard versus high dose CRT, and 0.8 (IQR 0.57, 0.88) versus 0.8 (IQR 0.66,0.91) with and without nelfinavir. Both scores were consistent across timepoints to week 6 post-CRT, at which point a fall in EQ-5D-5L but not the GHS score is seen across all studied cohorts (**Supp. Figs. 4-7**). No difference was seen in EORTC QLQ-C30 or EQ-5D-5L score between standard and high dose CRT (**Supp. Table 17 & 18, respectively**), and by nelfinavir usage (**Supp. Table 19 & 20, respectively**), at any of the assessed timepoints. Data relating to specific symptoms are provided in Appendix 2.

DISCUSSION

In the SCALOP-2 trial, neither radiotherapy dose escalation nor the putative radiosensitizer nelfinavir resulted in improved OS or PFS in patients with LAPC managed with capecitabine-based CRT. Radiotherapy dose escalation and nelfinavir were nevertheless well tolerated and the use of high-dose CRT correlated with numerically lower rates of local tumour progression. This was supported, albeit in a post-hoc analysis, by significantly better disease control six weeks after high-dose CRT.

The role of radiotherapy in the management of LAPC remains controversial. The LAP07 trial demonstrated that when used in patients with controlled disease following four months of

gemcitabine-based induction chemotherapy, three-dimensional conformal consolidation capecitabine-based CRT (54Gy in 30 fractions) was well tolerated and associated with lower rates of local progression (32% vs. 46%; $p=0.04$)¹². The use of CRT did not, however, translate to an improvement in median OS. This is perhaps unsurprising given that this cohort is at high risk of developing metastatic disease⁷. In LAP07 enhanced local control resulting from CRT nevertheless resulted in a longer interval to the next line of systemic therapy, which with an improvement in symptoms from locally progressive disease is postulated to result in improved HRQoL^{12,24,25}.

Here, rates of local progression at twelve months were 23.9% in the high dose CRT arm compared to 33.3% in the conventional dose arm. Although the small numbers do not allow formal statistical comparison, this increase in local control lends support to a growing body of evidence for a radiation dose-response relationship in this malignancy, albeit in the context of patients who receive induction chemotherapy^{26,27}. This apparent improvement in local control with high-dose CRT did not, however, translate to a sustained benefit in any of the assessed HRQoL measures when assessed up to seven months after completion of treatment. It is uncertain why this discrepancy exists, though the use of prolonged induction regimes such as those shown here may allow for prior optimization of cancer-related symptoms and may also select for patients with less aggressive disease biology. Regardless, CRT was well tolerated in this study and there was no additional radiation related toxicity in the high dose arm, providing strong evidence for the safety and tolerability of dose escalation using IMRT in the context of concurrent CRT. Indeed, whilst shorter term pancreatic pain and bowel habit appeared worse with higher-dose treatment, there was no detriment with respect to indigestion or eating related items despite previous modelling raising concerns for gastroduodenal toxicity from dose-escalated radiotherapy regimes^{13,14}. Patients who had received high-dose CRT also reported improved body image and sexuality.

The use of stereotactic body radiotherapy (SBRT), which is usually delivered in 3-5 daily or alternate day fractions, offers an alternative to CRT and is rapidly replacing CRT as the preferred consolidation regimen in patients with LAPC^{28,29}. The advantage to local control seen with high-dose CRT here is likely to extrapolate to the high radiation doses deliverable via SBRT. It may be that the more limited burden on patients from these shorter treatment regimens favours their use to achieve better local control, particularly if it allows for longer breaks in the use of systemic therapies or a reduction in local symptoms. SBRT may also achieve a lower incidence of radiation-induced lymphopenia as well as tumour-related complications such as pain and jaundice when compared to CRT^{24,30}.

An alternative means to improving the biological effect of radiotherapy is to identify efficacious drug radiotherapy combinations that overcome the intrinsic radioresistance of pancreatic cancer. The

antiretroviral protease inhibitor nelfinavir has shown promise as a potent radiosensitizer in preclinical models representing numerous malignancies³¹. This includes pancreatic cancer, in which its proposed mechanism of action centres on inhibition of the PI3K-Akt-mTOR pathway induction of endoplasmic reticulum stress and the unfolded protein response, vascular remodelling and tumour reoxygenation^{18-20,32,33}. Outcomes with nelfinavir were nevertheless disappointing. It is not clear why this is the case but the failure to repurpose nelfinavir in this study unfortunately reflects far broader challenges with translating promising novel drug-radiotherapy combinations from the bench to the bedside³⁴.

It is important to note that in this study, data relating to subsequent lines of treatment were available for only 41-58% of patients, with a suggestion of differences between treatment arms. The impact of this on the present data is unclear. Additionally, data relating to local tumour progression, which was not a primary outcome, may be influenced by relatively small patient numbers. The completeness of HRQoL data also falls over time, potentially opening data to influence from responder bias. Further, assessment of response by RECIST was not mandated, which may have led to some variation in response assessments.

It is also important to note that the systemic standard of care for patients with LAPC would now be regarded as FOLFIRINOX, rather than the induction gemcitabine/nabP doublet used here. This does not detract from the comparisons drawn between high and standard dose radiotherapy, nor those relating to nelfinavir use. One randomised phase II study comparing modified FOLFIRINOX versus gem/nab-paclitaxel in LAPC has demonstrated comparable efficacy between the regimens with lower GI toxicity in the gem/nab-paclitaxel arm³⁵. CONKO-007, a randomized phase III study comparing chemotherapy alone (FOLFIRINOX-77%; Gemcitabine-23%) with or without consolidation CRT has been reported in abstract form only³⁶. The 12 month PFS and OS in CONKO 007 (56% and 71% respectively) is comparable to that seen in this study as well as in the original SCALOP trial which used gemcitabine-capecitabine as the induction regimen; suggesting that the choice of induction chemotherapy may not necessarily influence survival outcomes.

This study is nevertheless the first randomized, prospective, comparison to report on CRT dose escalation and nelfinavir use, with comprehensive corresponding data presented here for their safety, toxicity and HRQoL. High-dose CRT is very well tolerated and appears to positively impact on local control. This favours further evaluation of the impact of radiotherapy dose escalation in the setting of LAPC, including using contemporary techniques such as SBRT.

REFERENCES

1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin* 2021; **71**(3): 209-49.
2. Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. *Lancet* 2011; **378**(9791): 607-20.
3. Suker M, Beumer BR, Sadot E, et al. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. *Lancet Oncol* 2016; **17**(6): 801-10.
4. Damm M, Efremov L, Birnbach B, et al. Efficacy and Safety of Neoadjuvant Gemcitabine Plus Nab-Paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Cancer-A Systematic Review and Meta-Analysis. *Cancers (Basel)* 2021; **13**(17).
5. Huguet F, André T, Hammel P, et al. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. *J Clin Oncol* 2007; **25**(3): 326-31.
6. Murphy JD, Adusumilli S, Griffith KA, et al. Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer. *Int J Radiat Oncol Biol Phys* 2007; **68**(3): 801-8.
7. Iacobuzio-Donahue CA, Fu B, Yachida S, et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. *J Clin Oncol* 2009; **27**(11): 1806-13.
8. Balaban EP, Mangu PB, Khorana AA, et al. Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. *J Clin Oncol* 2016; **34**(22): 2654-68.
9. Ducreux M, Cuhna AS, Caramella C, et al. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2015; **26 Suppl 5**: v56-68.
10. Gillen S, Schuster T, Meyer Zum Büschenfelde C, Friess H, Kleeff J. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. *PLoS Med* 2010; **7**(4): e1000267.
11. Hurt CN, Falk S, Crosby T, et al. Long-term results and recurrence patterns from SCALOP: a phase II randomised trial of gemcitabine- or capecitabine-based chemoradiation for locally advanced pancreatic cancer. *Br J Cancer* 2017; **116**(10): 1264-70.
12. Hammel P, Huguet F, van Laethem JL, et al. Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial. *Jama* 2016; **315**(17): 1844-53.
13. Holyoake DLP, Warren DR, Hurt C, et al. Stomach Dose-Volume Predicts Acute Gastrointestinal Toxicity in Chemoradiotherapy for Locally Advanced Pancreatic Cancer. *Clin Oncol (R Coll Radiol)* 2018; **30**(7): 418-26.
14. Kelly P, Das P, Pinnix CC, et al. Duodenal toxicity after fractionated chemoradiation for unresectable pancreatic cancer. *Int J Radiat Oncol Biol Phys* 2013; **85**(3): e143-9.
15. Gupta AK, Cerniglia GJ, Mick R, McKenna WG, Muschel RJ. HIV protease inhibitors block Akt signaling and radiosensitize tumor cells both in vitro and in vivo. *Cancer Res* 2005; **65**(18): 8256-65.
16. Pajonk F, Himmelsbach J, Riess K, Sommer A, McBride WH. The human immunodeficiency virus (HIV)-1 protease inhibitor saquinavir inhibits proteasome function and causes apoptosis and radiosensitization in non-HIV-associated human cancer cells. *Cancer Res* 2002; **62**(18): 5230-5.
17. Kimple RJ, Vaseva AV, Cox AD, et al. Radiosensitization of epidermal growth factor receptor/HER2-positive pancreatic cancer is mediated by inhibition of Akt independent of ras mutational status. *Clin Cancer Res* 2010; **16**(3): 912-23.
18. Veschi S, De Lellis L, Florio R, et al. Effects of repurposed drug candidates nitroxoline and nelfinavir as single agents or in combination with erlotinib in pancreatic cancer cells. *J Exp Clin Cancer Res* 2018; **37**(1): 236.

19. Wilson JM, Fokas E, Dutton SJ, et al. ARCI: A phase II trial of the HIV protease inhibitor Nelfinavir in combination with chemoradiation for locally advanced inoperable pancreatic cancer. *Radiother Oncol* 2016; **119**(2): 306-11.
20. Brunner TB, Geiger M, Grabenbauer GG, et al. Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer. *J Clin Oncol* 2008; **26**(16): 2699-706.
21. Strauss VY, Shaw R, Virdee PS, et al. Study protocol: a multi-centre randomised study of induction chemotherapy followed by capecitabine ± nelfinavir with high- or standard-dose radiotherapy for locally advanced pancreatic cancer (SCALOP-2). *BMC Cancer* 2019; **19**(1): 121.
22. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. *Bmj* 2010; **340**: c332.
23. Philip PA, Lacy J, Portales F, et al. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study. *Lancet Gastroenterol Hepatol* 2020; **5**(3): 285-94.
24. Vornhülz M, Anton S, Eross B, et al. Role of stereotactic body radiation in the enhancement of the quality of life in locally advanced pancreatic adenocarcinoma: a systematic review. *Radiat Oncol* 2022; **17**(1): 108.
25. Hurt CN, Mukherjee S, Bridgewater J, et al. Health-Related Quality of Life in SCALOP, a Randomized Phase 2 Trial Comparing Chemoradiation Therapy Regimens in Locally Advanced Pancreatic Cancer. *Int J Radiat Oncol Biol Phys* 2015; **93**(4): 810-8.
26. Golden DW, Novak CJ, Minsky BD, Liauw SL. Radiation dose ≥54 Gy and CA 19-9 response are associated with improved survival for unresectable, non-metastatic pancreatic cancer treated with chemoradiation. *Radiat Oncol* 2012; **7**: 156.
27. Moraru IC, Tai A, Erickson B, Li XA. Radiation dose responses for chemoradiation therapy of pancreatic cancer: an analysis of compiled clinical data using biophysical models. *Pract Radiat Oncol* 2014; **4**(1): 13-9.
28. Suker M, Nuyttens JJ, Eskens F, et al. Efficacy and feasibility of stereotactic radiotherapy after folfirinox in patients with locally advanced pancreatic cancer (LAPC-1 trial). *EClinicalMedicine* 2019; **17**: 100200.
29. Tchelebi LT, Lehrer EJ, Trifiletti DM, et al. Conventionally fractionated radiation therapy versus stereotactic body radiation therapy for locally advanced pancreatic cancer (CRiSP): An international systematic review and meta-analysis. *Cancer* 2020; **126**(10): 2120-31.
30. Wild AT, Herman JM, Dholakia AS, et al. Lymphocyte-Sparing Effect of Stereotactic Body Radiation Therapy in Patients With Unresectable Pancreatic Cancer. *Int J Radiat Oncol Biol Phys* 2016; **94**(3): 571-9.
31. Goda JS, Pachpor T, Basu T, Chopra S, Gota V. Targeting the AKT pathway: Repositioning HIV protease inhibitors as radiosensitizers. *Indian J Med Res* 2016; **143**(2): 145-59.
32. Pore N, Gupta AK, Cerniglia GJ, et al. Nelfinavir down-regulates hypoxia-inducible factor 1 α and VEGF expression and increases tumor oxygenation: implications for radiotherapy. *Cancer Res* 2006; **66**(18): 9252-9.
33. Al-Assar O, Bittner MI, Lunardi S, Stratford MR, McKenna WG, Brunner TB. The radiosensitizing effects of Nelfinavir on pancreatic cancer with and without pancreatic stellate cells. *Radiother Oncol* 2016; **119**(2): 300-5.
34. Ahmad SS, Crittenden MR, Tran PT, et al. Clinical Development of Novel Drug-Radiotherapy Combinations. *Clin Cancer Res* 2019; **25**(5): 1455-61.
35. Ozaka M, Nakachi K, Kobayashi S, et al. A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407). *Eur J Cancer* 2023; **181**: 135-44.
36. Rainer Fietkau MG, Robert Grützmann, Uwe A Wittel, Lutz Jacobasch, Waldemar Uhl, Roland S. Croner, Wolf Otto Bechstein, Ulf Peter Neumann, Dirk Waldschmidt, Stefan Hubert Boeck, Nicolas Moosmann, Anke C. Reinacher-Schick, Henriette Golcher, Werner Adler, Sabine Semrau, Annett

Kallies, Markus Hecht, Andrea Tannapfel, and Helmut Oettle. Randomized phase III trial of induction chemotherapy followed by chemoradiotherapy or chemotherapy alone for nonresectable locally advanced pancreatic cancer: First results of the CONKO-007 trial. *Journal of Clinical Oncology* 2022; **40**.

CONTRIBUTORS

SM, CQ, CNH, PSV and RS contributed to the design and development of the trial. SM, CQ, RS, NP, JH, PP, PSV and BT contributed to the writing and review of the protocol. SM, CQ, RS, NP, JH, PSV, BT and PP were involved in the day-to-day running of the trial. SM, CQ, CMJ, JH and PSV were responsible for statistical analysis and data interpretation. SM, JAB, GR, SF, HSW, TVA, DH, RR, MSB, CNH, DSM, TSM, MAH and PC contributed to the recruitment of patients and study management. SM, CQ, CMJ, NP, JH, PSV, CNH and BT contributed to the analysis and interpretation of data. CQ and CMJ provided data representations. CMJ drafted the first version of the manuscript. All authors have contributed to, seen and approved the final draft of the manuscript.

CONFLICTS OF INTEREST

The authors declare that they have no conflicts of interest.

DATA SHARING

The data collected for the study, including individual participant data and a data dictionary defining each field in the set, will be made available to researchers on request to the study team and with appropriate reason, via octo-enquiries@oncology.ox.ac.uk. The shared data will be de-identified participant data and will be available for 5 years following publication of the study. Data will be shared with investigator support, after approval of a proposal and with a signed data access agreement.

ACKNOWLEDGEMENTS

The SCALOP-2 trial was sponsored by the University of Oxford and funded by Cancer Research UK (CRUK/07/040). Trial management was provided by the Oncology Clinical Trials Office (OCTO) at the University of Oxford as part of the UKCRC Oxford Clinical Trials Research Unit (OCTRU). Statistical input was provided by Centre for Statistics in Medicine (CSM) at the University of Oxford. This work was funded by Cancer Research UK (C28958/A17139). Celgene provided additional financial support and

nab-paclitaxel free of charge. Radiotherapy Trials Quality Assurance by National Radiotherapy Trials (RTTQA) Group. Celgene provided an education grant and nab-paclitaxel without charge. CMJ is supported by a Clinical Lectureship part-funded by Cancer Research UK RadNet Cambridge (C17918/A28870). MAH is supported by funding from the National Institute for Health Research (NIHR) Biomedical Research Centre at University College London Hospitals NHS Foundation Trust. PC received support from the NIHR Cambridge Biomedical Research Centre. We are grateful to the patients who participated in this trial, and to the clinicians and wider multidisciplinary teams that recruited and cared for them. The authors additionally extend their thanks to members of the TSC, DSMC and to members of the SRC. Finally, we are grateful to Mrs. Susan H. Campbell for her invaluable support and advice as the group's patient and public involvement representative.

LIST OF TABLES

Table 1: Baseline patient and tumour characteristics for patients enrolled in stage 2 of the SCALOP-2 trial. Data are n (%) or median (lower quartile, upper quartile). Where the numbers with available data are different to the column total, the numbers included is indicated by (n=). The minimisation factors were World Health Organisation Performance Status at randomisation and site of primary tumour. Arm E was initially planned as a calibration arm but was closed to recruitment in November 2019 due to the availability of other reference data.

Table 2: Compliance with specific components of chemoradiotherapy by treatment arm. Data are n (%).

Table 3: A summary of adverse events reported during chemoradiotherapy, subdivided by trial arms and grade of severity. Only one patient, who was in the high-dose CRT arm, experienced an adverse event related to nelfinavir.

Table 4: A summary of secondary endpoints relating to disease control measures. *Number randomised. **Number randomised before closure of arms A and C. ***One-sided value.

LIST OF FIGURES

Figure 1: CONSORT flow diagram of stage 2 of the SCALOP-2 trial. Cape, capecitabine; CRT, chemoradiotherapy; Nelf, nelfinavir, gem, gemcitabine; nabP, nab-paclitaxel.

Figure 2: Kaplan-Meier estimates for stage 2 patients receiving chemoradiotherapy of (A) overall survival by standard versus high dose radiation and (B) progression-free survival by nelfinavir usage.

Figure 3: Change in EORTC-PAN26 score from prior to, to immediately, 6-, 18- and 28- weeks following standard (50.4Gy in 28 fractions) and high (60Gy in 30 fractions) dose chemoradiotherapy.

Figure 4: Change in EORTC-PAN26 score from prior to, to immediately, 6-, 18- and 28- weeks following chemoradiotherapy with and without concurrent nelfinavir.

SUPPLEMENTARY MATERIALS

APPENDICES

Appendix 1: Protocol for the SCALOP-2 trial. The most recent version of the SCALOP-2 (A multi-centre randomized study of induction chemotherapy followed by capecitabine (+/- nelfinavir) with high or standard dose radiotherapy for locally advanced non-metastatic pancreatic cancer) trial protocol.

Appendix 2: Supplementary information.

FIGURES

Supplementary figure 1: CONSORT flow diagram of stage 1 of the SCALOP-2 trial.

Supplementary figure 2: Kaplan-Meier estimates for stage 2 patients receiving chemoradiotherapy of overall survival by radiation dose in (A) patients randomized to nelfinavir and (B) patients who were not randomized to nelfinavir.

Supplementary figure 3: Kaplan Meier estimates for stage 2 patients receiving chemoradiotherapy of progression-free survival by nelfinavir usage in (A) patients randomized to standard dose radiation and (B) patients randomized to high dose radiation.

Supplementary figure 4: Global Health Status score by stage 2 treatment arm (standard versus high dose chemoradiotherapy)

Supplementary figure 5: Global Health Status score by stage 2 treatment arm (with or without nelfinavir)

Supplementary figure 6: EQ-5D-5L score by stage 2 treatment arm (standard versus high dose chemoradiotherapy)

Supplementary figure 7: EQ-5D-5L score by stage 2 treatment arm (with or without nelfinavir)

TABLES

Supplementary table 1: A list of centres that recruited to stages 1 and 2 of the SCALOP-2 trial. All centres are secondary or tertiary cancer centres that form part of the National Health Service in the United Kingdom. Principal Investigators based at each respective site are shown, as is whether they participated in stages 1 and 2 or only stage 2.

Supplementary table 2: A summary of reasons for withdrawal from stage 2 prior to randomisation.

Each reason for withdrawal is listed below the relevant timepoint at which withdrawal from the study occurred.

Supplementary table 3: Baseline patient and tumour characteristics for patients enrolled in stage 1 of the SCALOP-2 trial. ¹% (n) for categorical variables (percentage calculated using the total number in the respective group); median (min-max) for continuous variables

Supplementary table 4: A summary of missing data items for each of the stage 2 trial arms. Of the fourteen patients for whom there was missing data for largest diameter of primary lesion, four did not have a recorded measurement available and for the remainder the diameter was not measurable.

Supplementary table 5: A summary of subsequent treatment by stage 2 study arm. ¹The median time is out of patients who received subsequent treatment (second row), it is descriptive i.e. not Kaplan-Meier.

Supplementary table 6: A summary of adverse events reported during stage 1 of the trial, by nelfinavir dose. Percentages are shown as a proportion of the total number of patients in each dose group.

Supplementary table 7: A summary of the overall, and grade 3/4, adverse event rate prior to and following the start of chemoradiotherapy, by radiation dose.

Supplementary table 8: A summary of the overall, and grade 3/4, adverse event rate prior to and following the start of chemoradiotherapy, with and without nelfinavir.

Supplementary table 9: Rate of adverse events & serious adverse events (SAEs) attributed to nelfinavir.

Supplementary table 10: A summary of adverse events reported prior to the first fraction of chemoradiotherapy, subdivided by trial arms and grade of severity.

Supplementary table 11: Per-protocol analyses for overall survival by radiation dose and progression free survival by nelfinavir usage.

Supplementary table 12: Sensitivity analyses for overall survival by radiation dose and progression free survival by nelfinavir usage.

Supplementary table 13: Data relating to local control at one year, by study arm. *Events refer to the first recorded event. Events where both local and distant progression were present at first diagnosis of progression are recorded as local progression (with or without metastasis).

Supplementary table 14: Survival and disease control outcomes for stage 2 trial arm E.

Supplementary table 15: Survival and disease control outcomes for the observation cohort.

Supplementary table 16: Data availability for each of the three assessed health-related quality measures at each of the five assessed timepoints. *Sixty patients were alive to 28 calendar weeks after CRT but one additional patient took the questionnaire early, prior to death, and has been included.

Supplementary table 17: EORTC QLQ-C30 score by chemoradiotherapy dose. *Model adjusting for time point (end of CRT/6/18/28 weeks post-CRT), GHS score at the start of CRT, RT treatment group (arms A+B vs C+D), nelfinavir assignment (arms A+C or B+D), WHO PS (0 or 1), disease location (head or body/tail) and RT treatment group*timepoint interaction. Model included a random intercept for patient effect.

Supplementary table 18: EQ-5D-5L score by CRT dose. *Model adjusting for time point (end of CRT/6/18/28 weeks post-CRT), GHS score at the start of CRT, RT treatment group (arms A+B vs C+D), nelfinavir assignment (arms A+C or B+D), WHO PS (0 or 1), disease location (head or body/tail) and RT treatment group*timepoint interaction. Model included a random intercept for patient effect.

Supplementary table 19: EORTC QLQ-C30 score by nelfinavir use. *Model adjusting for time point (end of CRT/6/18/28 weeks post-CRT), GHS score at the start of CRT, RT treatment group (arms A+B vs C+D), nelfinavir assignment (arms A+C or B+D), WHO PS (0 or 1), disease location (head or body/tail) and RT treatment group*timepoint interaction. Model included a random intercept for patient effect.

Supplementary table 20: EQ-5D-5L score by nelfinavir use. *Model adjusting for time point (end of CRT/6/18/28 weeks post-CRT), GHS score at the start of CRT, RT treatment group (arms A+B vs C+D), nelfinavir assignment (arms A+C or B+D), WHO PS (0 or 1), disease location (head or body/tail) and RT treatment group*timepoint interaction. Model included a random intercept for patient effect.

Supplementary table 21: Adjusted mean difference in EORTIC-PAN26 score immediately, 6-, 18- and 28- weeks following standard (50.4Gy in 28 fractions) and high (60Gy in 30 fractions) dose chemoradiotherapy. *Model adjusting for time point (end of CRT/6/18/28 weeks post-CRT), GHS score at the start of CRT, RT treatment group (arms A+B vs C+D), nelfinavir assignment (arms A+C or B+D), WHO PS (0 or 1), disease location (head or body/tail) and RT treatment group*timepoint interaction. Model included a random intercept for patient effect.

Supplementary table 22: Adjusted mean difference in EORTIC-PAN26 score immediately, 6-, 18- and 28- weeks following chemoradiotherapy with and without concurrent nelfinavir. *Model adjusting

for time point (end of CRT/6/18/28 weeks post-CRT), GHS score at the start of CRT, RT treatment group (arms A+B vs C+D), nelfinavir assignment (arms A+C or B+D), WHO PS (0 or 1), disease location (head or body/tail) and RT treatment group*timepoint interaction. Model included a random intercept for patient effect.